Last reviewed · How we verify
NCT07318129: iPROACT-MS
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
NA trial testing Placebo in Relapsing Remitting Multiple Sclerosis (RRMS) in 220 participants. Currently enrolling.
15 July 2028
Quick facts
| Lead sponsor | Glostrup University Hospital, Copenhagen |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 26 January 2026 |
| Primary completion | 15 July 2028 |
| Estimated completion | 15 July 2028 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Placebo
- Indole-3-propionic acid (IPA)
Conditions studied
- Relapsing Remitting Multiple Sclerosis (RRMS) — all drugs for Relapsing Remitting Multiple Sclerosis (RRMS) →
Sponsor
Glostrup University Hospital, Copenhagen
Who can join
Adults 18 to 65, any sex, with Relapsing Remitting Multiple Sclerosis (RRMS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07318129
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Indole-3-propionic acid (IPA)
Trials testing the same drug.
- NCT07105514 — Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2 · NA · recruiting
Other recruiting trials for Relapsing Remitting Multiple Sclerosis (RRMS)
Currently open trials in the same condition.
- NCT06733922 — ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS · Phase 4 · recruiting
- NCT07497126 — The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Scleros · active not recruiting
Other Glostrup University Hospital, Copenhagen trials
Trials by the same sponsor.
- NCT07442773 — Intervention to Support Partners and Informal Caregivers of Frail RA-patients · NA · recruiting
- NCT07105514 — Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2 · NA · recruiting
- NCT06533423 — Effect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: The NISMA Trial · NA · recruiting
- NCT06674018 — Indole-3-PROpionic Acid Clinical Trials - a Pilot Study · NA · completed
- NCT05213286 — The Development of a Screening Questionnaire to Discriminate Autism Spectrum Disorder and Schizotypal Disorder, and Vali · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07318129 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Glostrup University Hospital, Copenhagen
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07318129.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing